BiotechTube

Placebo ophthalmic solution and 3% DE-089 ophthalmic solution

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Eye Disease

Conditions

Dry Eye Disease

Trial Timeline

Sep 8, 2017 → Feb 1, 2018

NCT ID
NCT03216096

About Placebo ophthalmic solution and 3% DE-089 ophthalmic solution

Placebo ophthalmic solution and 3% DE-089 ophthalmic solution is a phase 1 stage product being developed by Santen Pharmaceutical for Dry Eye Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03216096. Target conditions include Dry Eye Disease.

What happened to similar drugs?

20 of 20 similar drugs in Dry Eye Disease were approved

Approved (20) Terminated (1) Active (0)
✅EvolocumabHeartFlowApproved
✅Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
✅Infliximab + Infliximab + InfliximabCelltrionApproved
✅YMC026 + PlaceboYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03216096Phase 1Completed

Competing Products

20 competing products in Dry Eye Disease

See all competitors
ProductCompanyStageHype Score
COVID-19 VaccineModernaPreclinical
0
exidavnemab + Placebo ComparatorBioArctic ABPhase 2
36
mRNA-1975ModernaPhase 2
0
mRNA-3745ModernaPhase 2
0
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
UB-312 + PlaceboVaxxinityPhase 1
19
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
21
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
Abiprubart + PlaceboKiniksa PharmaceuticalsPhase 2
21
atomoxetine + Matching PlaceboEli LillyPhase 2
35
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
27
EvolocumabHeartFlowApproved
29
High intensity lipid loweringHeartFlowPre-clinical
20
Apixaban 5 MG + Apixaban 2.5 MG + WarfarinArtivionPhase 3
26
LanifibranorInventivaPhase 2
29
LY450139 + PlaceboEli LillyPhase 3
40
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
21
Solanezumab + PlaceboEli LillyPhase 3
32